Pegylated interferon for chronic hepatitis B
Editorial Group: Cochrane Hepato-Biliary Group
Published Online: 24 JAN 2007
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Mumtaz K, Hamid S, Jafri W. Pegylated interferon for chronic hepatitis B (Protocol). Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD006303. DOI: 10.1002/14651858.CD006303.
- Publication Status: Edited (no change to conclusions)
- Published Online: 24 JAN 2007
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the beneficial and harmful effects of pegylated interferon alpha-2a (40 kilodalton (kd)) or pegylated interferon alpha-2b (12 kd) alone or in combination with other drugs, as compared with no treatment, placebo, or other antiviral drugs (except adefovir dipivoxil) for chronic hepatitis B, with HBeAg-positive or HBeAg-negative status.